Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29801823 | 1.00 | NR1H2 (0.46) | NR1H2JAK3GPR119USP2SMN1; SMN2 | |
| SCHEMBL10067585 | 1.00 | NR1H2 (0.46) | NR1H2JAK3GPR119USP2SMN1; SMN2 | |
| SCHEMBL9963036 | 1.00 | NR1H2 (0.46) | NR1H2JAK3GPR119USP2SMN1; SMN2 | |
| SCHEMBL25394475 | 0.91 | GPR119 (0.40) | GPR119MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL29674207 | 0.86 | NR1H2 (0.54) | NR1H2GPR119USP2SMN1; SMN2NAMPT | |
| SCHEMBL23149385 | 0.86 | NR1H2 (0.50) | NR1H2GPR119MEN1ALDH1A1MAPT | |
| SCHEMBL26132616 | 0.86 | NR1H2 (0.43) | NR1H2JAK3GPR119USP2SMN1; SMN2 | |
| SCHEMBL16053073 | 0.85 | NR1H2 (0.48) | NR1H2GPR119USP2SMN1; SMN2NAMPT | |
| SCHEMBL445759 | 0.85 | NR1H2 (0.51) | NR1H2GPR119USP2SMN1; SMN2NAMPT | |
| SCHEMBL17310897 | 0.85 | NR1H2 (0.48) | NR1H2GPR119USP2SMN1; SMN2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072451-A1 | RAS-PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOLOGICAL DISEASES | VIVIDION THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| EP-4506344-A1 | 1,4-DIHETEROCYCLIC SUBSTITUTED AROMATIC RING OR AROMATIC HETEROCYCLIC COMPOUND AND USE THEREOF | Bebetter Med Inc. (CN) | 2025-02-12 | — | — | EP | disclosed |
| US-20250034116-A1 | 1,4-DIHETEROCYCLIC SUBSTITUTED AROMATIC RING OR AROMATIC HETEROCYCLIC COMPOUND AND USE THEREOF | BEBETTER MED INC. (CN) | 2025-01-30 | — | — | US | disclosed |
| CN-116615417-B | 1, 4-Diheterocyclic group substituted aromatic ring or aromatic heterocyclic compound and application thereof | 广州必贝特医药股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2023185821-A1 | 1,4-DIHETEROCYCLIC SUBSTITUTED AROMATIC RING OR AROMATIC HETEROCYCLIC COMPOUND AND USE THEREOF | 广州必贝特医药股份有限公司 | 2023-10-05 | — | — | WO | disclosed |
| US-20230135552-A1 | Compounds Useful In Inhibiting Ketohexokinase And Methods Of Making And Using The Same | INORBIT THERAPEUTICS AB (SE) | 2023-05-04 | — | — | US | disclosed |
| EP-4106762-A1 | COMPOUNDS USEFUL IN INHIBITING KETOHEXOKINASE AND METHODS OF MAKING AND USING THE SAME | INORBIT THERAPEUTICS AB (SE) | 2022-12-28 | — | — | EP | disclosed |
| EP-3265459-B1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2019-05-15 | — | — | EP | disclosed |
| EP-3265459-B1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2019-05-15 | — | — | EP | disclosed |
| EP-2976337-B1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2018-05-02 | — | — | EP | disclosed |
| US-20160280694-A1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-09-29 | — | — | US | disclosed |
| US-20160280694-A1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-09-29 | — | — | US | disclosed |
| US-20160280694-A1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-09-29 | — | — | US | disclosed |
| WO-2016128990-A1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016128990-A1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-08-18 | — | — | WO | disclosed |
| EP-2976337-A1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | Suven Life Sciences Limited (IN) | 2016-01-27 | — | — | EP | disclosed |
| WO-2015092804-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015092804-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2015-06-25 | — | — | WO | disclosed |
| WO-2014147636-A1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2014-09-25 | — | — | WO | disclosed |
| WO-2012041158-A1 | TRICYCLIC COMPOUND, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 上海恒瑞医药有限公司 (CN) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280694-A1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | NR1H2 948/4885JAK3 1382/4885GPR119 145/4885 |
| US-20250034116-A1 | 1,4-DIHETEROCYCLIC SUBSTITUTED AROMATIC RING OR AROMATIC HETEROCYCLIC COMPOUND AND USE THEREOF | CYP46A1, CYP4A22, CYP2C19 | NR1H2 94/4885JAK3 1653/4885GPR119 326/4885 |
| US-20230135552-A1 | Compounds Useful In Inhibiting Ketohexokinase And Methods Of Making And Using The Same | KHK, GCK, HK1 | NR1H2 2251/4885JAK3 2995/4885GPR119 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.